Literature DB >> 19232553

Development of a Core Set Questionnaire by the European Society of Cutaneous Lupus Erythematosus (EUSCLE).

A Kuhn1, E Kuehn, A M Meuth, M Haust, F Nyberg, V Werth, T Ruzicka, V Schmitt, G Bonsmann.   

Abstract

A study group of the European Society of Cutaneous Lupus Erythematosus (EUSCLE) developed a Core Set Questionnaire for the evaluation of patients with cutaneous lupus erythematosus (CLE). The aim of the EUSCLE Core Set Questionnaire is to gain a broad and comparable data collection of patients with CLE from different European centers, to achieve consensus concerning evidence-based clinical standards for disease assessment, and to develop diagnostic and therapeutic guidelines. The authors designed the EUSCLE Core Set Questionnaire by including parameters considered most relevant for the evaluation of CLE and compiled from international literature, clinical praxis, and long-term experience with this disease. The compilation of the different parameters for the evaluation of CLE resulted in the 4-sided EUSCLE Core Set Questionnaire with six sections on patient data, diagnosis, skin involvement, activity and damage of disease, laboratory analysis, and treatment. Thus, the EUSCLE Core Set Questionnaire for CLE constitutes a useful tool for the collection and evaluation of epidemiological data from patients with this disease. It enables consistent statistical evaluation, exchange, and comparison of patient's data within several European countries and provides a set of guidelines for standardized diagnostic and therapeutic strategies in CLE.

Entities:  

Mesh:

Year:  2009        PMID: 19232553     DOI: 10.1016/j.autrev.2009.02.022

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN: 1568-9972            Impact factor:   9.754


  6 in total

1.  Cigarette smoking and response to antimalarials in cutaneous lupus erythematosus patients: evolution of a dogma.

Authors:  Jan Dutz; Victoria P Werth
Journal:  J Invest Dermatol       Date:  2011-10       Impact factor: 8.551

Review 2.  Treatment of cutaneous lupus.

Authors:  Aileen Y Chang; Victoria P Werth
Journal:  Curr Rheumatol Rep       Date:  2011-08       Impact factor: 4.592

Review 3.  Rheumatic manifestations of skin disease.

Authors:  Jennie T Clarke; Victoria P Werth
Journal:  Curr Opin Rheumatol       Date:  2010-01       Impact factor: 5.006

4.  Update on the use of topical calcineurin inhibitors in cutaneous lupus erythematosus.

Authors:  Michael Sticherling
Journal:  Biologics       Date:  2011-02-14

5.  From pathogenesis, epidemiology, and genetics to definitions, diagnosis, and treatments of cutaneous lupus erythematosus and dermatomyositis: a report from the 3rd International Conference on Cutaneous Lupus Erythematosus (ICCLE) 2013.

Authors:  Heather Y Schultz; Jan P Dutz; Fukumi Furukawa; Mark J Goodfield; Annegret Kuhn; Lela A Lee; Filippa Nyberg; Jacek C Szepietowski; Richard D Sontheimer; Victoria P Werth
Journal:  J Invest Dermatol       Date:  2015-01       Impact factor: 8.551

Review 6.  Systematic Review: Monoclonal Antibody-Induced Subacute Cutaneous Lupus Erythematosus.

Authors:  Chrissy Bolton; Yifan Chen; Rachel Hawthorne; Ianthe R M Schepel; Elinor Harriss; Silke C Hofmann; Spencer Ellis; Alexander Clarke; Helena Wace; Blanca Martin; Joel Smith
Journal:  Drugs R D       Date:  2020-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.